Evidence map›Paper›PMID 39911262›Full record

ArticleInternational journal of nanomedicine2025

An Injectable Hydrogel Bioimplant Loaded with Engineered Exosomes and Triple Anti-Tuberculosis Drugs with Potential for Treating Bone and Joint Tuberculosis.

Jiayan Huang, Han Li, Yuting Mei, Pengcheng Yi, Yunyao Ren, Yunjuan Wang, Limei Han, Qiusha Tang, Dongfang Liu, Wei Chen and 2 more

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiayan Huang *Department of Tuberculosis, the Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Han Li *Department of Pharmacy, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, People's Republic of China.
Yuting MeiDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Pengcheng YiDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Yunyao RenDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Yunjuan WangMedical School of Southeast University, Nanjing, People's Republic of China.
Limei HanDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Qiusha TangMedical School of Southeast University, Nanjing, People's Republic of China.
Dongfang LiuMedical School of Southeast University, Nanjing, People's Republic of China.
Wei ChenDepartment of Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.ORCID 0000-0003-1526-4677
Yanli AnNurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Medical School, Zhong da Hospital, Southeast University, Nanjing, Jiangsu People's Republic of China.
Chunmei HuDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.ORCID 0000-0002-3788-4191

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Treatment for bone and joint tuberculosis (BJTB) is challenging due to its refractory and recurrent nature. This study aimed to develop a bioimplantable scaffold with osteoinductive and antituberculosis characteristics to treat BJTB. Methods: This scaffold is built on oxidized hyaluronic acid and carboxymethyl chitosan hydrogel mixed with hydroxyapatite as a bone tissue engineered material. In order to make the scaffold have the biological activity of promoting tissue repair, the engineered exosomes (Exo Results: The designed scaffold has characteristics of self-healing and injectability exhibit excellent anti-tuberculosis and promoting bone repair activities. Exo Conclusion: The composite bio-scaffold shows good tissue repair and long-term anti-tuberculosis abilities, which expected to provide a viable treatment plan for bone-related BJTB.

Indexed as

Antitubercular AgentsExosomesHydrogelsTuberculosis, OsteoarticularAnimalsCell DifferentiationChitosanDrug LiberationDurapatiteHumansHyaluronic AcidLiposomesMesenchymal Stem CellsOsteogenesisTissue EngineeringTissue ScaffoldsAntitubercular AgentsChitosanDurapatiteHyaluronic AcidHydrogelsLiposomesbone and joint tuberculosisengineered exosomeshydrogel scaffoldstherapytriple anti-tuberculosis drugs loaded

Identifiers

PMID39911262
PMCPMC11794387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.